Journal of Ophthalmology / 2011 / Article / Tab 1 / Clinical Study
One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study Table 1 Baseline characteristics and ranibizumab treatment.
ITT population (
) On-treatment population (
) Baseline age (years)
Range 46–93 46–93 Gender,
(%) Male 160 (34.0%) 123 (33.2%) Female 311 (66.0%) 247 (66.8%) Indication for ranibizumab,
(%) Wet AMD 468 (99.4%) 368 (99.5%) Other 3 (0.6%) 2 (0.5%) Baseline OCT performed,
(%) Yes 357 (75%) 242 (75%) No 115 (24%) 82 (25%) Unknown 2 (0.4%) 0 Baseline ETDRS,
(%) Yes 337 (71%) 223 (69%) No 136 (28.6%) 101 (31%) Unknown 2 (0.4%) 0 Initial 3 ranibizumab injections,
(%) No 1 11 (2.3%) 3 (0.8%) 2 25 (5.3%) 15 (4.1%) Yes 435 (92.4%) 352 (95.1%) Total number of ranibizumab injections (≤12 months) (12 months)
.6 Range 0–10 1–10 Number of visits (≤12 months) (12 months)
9
.6
.8 Range 1–14 5–14 Discontinuation before month 12,
(%) 101 (21.4%) Reason for discontinuation,
(%) Withdrawal of informed consent 2 (0.4%) — Decline further injections 6 (1.2%) — Serious complication 1 (0.2%) — Retinal detachment 0 — Referred for continuous follow up 7 (1.5%) — Physician’s decision that no further 34 (7.2%) — followup is necessary Other reason 43 (9.1%) — Unknown 8 (1.7%) —